ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 16 No. 2 (2023), REVIEWS
Vol. 16 No. 2 (2023)
REVIEWS

Morpho-Immunohistochemical Characteristics of Different Mycosis Fungoides Stages: A Literature Review

Published 20.02.2024
Andrei Alekseevich Sherstnev
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
A.M. Kovrigina
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
2023-2
PDF_2023-16-2_109-118 (Russian)

Keywords

mycosis fungoides
naive T-cells
T-helper cells
reactive microenvironment

How to Cite

Sherstnev A.A., Kovrigina A.M. Morpho-Immunohistochemical Characteristics of Different Mycosis Fungoides Stages: A Literature Review. Clinical Oncohematology. 2024;(2):109–118. doi:10.21320/2500-2139-2023-16-2-109-118.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Mycosis fungoides (MF) is the most ubiquitous type of cutaneous T-cell lymphoma. MF pathogenesis has not been well studied up to now. Differential diagnosis of the disease, especially at early stages, is complicated and poses a considerable challenge. The present review covers current views on MF pathogenesis and methods of its diagnosis.

PDF_2023-16-2_109-118 (Russian)

References

  1. Кохан М.М. Т-клеточные злокачественные лимфомы кожи: клинические и иммунологические аспекты диагностики, стадийного течения и терапии: Автореф. … д-ра мед. наук. М., 2002.
  2. [Kokhan MM. T-kletochnye zlokachestvennye limfomy kozhi: klinicheskie i immunologicheskie aspekty diagnostiki, stadiinogo techeniya i terapii. (Cutaneous T-cell malignant lymphomas: clinical and immunological aspects of diagnosis, stage course, and therapy.) [dissertation] Moscow; 2002. (In Russ)]
  3. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85. doi: 10.1182/blood-2004-09-3502.
  4. Korgavkar K, Xiong M, Weinstock М. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295–9. doi: 10.1001/jamadermatol.2013.5526.
  5. Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54(4):752–9. doi: 10.3109/10428194.2012.729831.
  6. Tan RH, Butterworth CM, McLaughlin H, et al. Mycosis fungoides—a disease of antigen persistence. Br J Dermatol. 1974;91(6):607–16. doi: 1111/j.1365-2133.1974.tb12449.x.
  7. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–71. doi: 10.1182/blood-2009-11-251926.
  8. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. 2002;99(8):2929–39. doi: 10.1182/blood.V99.8.2929.
  9. Wang L, Ni X, Covington K, et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015;47(12):1426–34. doi: 10.1038/ng.3444.
  10. Krejsgaard T, Willerslev-Olsen A, Lindahl LM, et al. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood. 2014;124(5):761–70. doi: 10.1182/blood-2014-01-551184.
  11. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–201. doi: 10.1038/sj.jid.5700410.
  12. Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992–1002. doi: 10.1016/j.jaad.2015.02.1116.
  13. Mirvish JJ, Pomerantz RG, Falo Jr LD, et al. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol. 2013;31(4):423–31. doi: 10.1016/j.clindermatol.2013.01.009.
  14. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64(2):423–31. doi: 10.1016/j.jaad.2009.11.692.
  15. Белоусова И.Э., Самцов А.В. Федеральные клинические рекомендации по ведению больных лимфомами кожи. М., 2015. С. 13–25.
  16. [Belousova IE, Samtsov AV. Federalnye klinicheskie rekomendatsii po vedeniyu bolnykh limfomami kozhi. (Federal clinical guidelines for management of patients with cutaneous lymphomas.) Moscow; 2015. pp. 13–25. (In Russ)]
  17. Larocca C, Kupper T. Mycosis fungoides and sezary syndrome: an update. Hematol Oncol Clin. 2019;33(1):103–20. doi: 10.1016/j.hoc.2018.09.001.
  18. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–9. doi: 10.1200/jco.2009.27.7665.
  19. Sun G, Berthelot C, Li Y, Glass DA. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009;60(2):231–5. doi: 10.1016/j.jaad.2008.09.063.
  20. Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–60. doi: 10.1158/1078-0432.ccr-12-0604.
  21. Молочков А.В., Ковригина А.М., Кильдюшевский А.В., Караулов А.В. Лимфома кожи. М.: БИНОМ, 2012. 183 с.
  22. [Molochkov AV, Kovrigina AM, Kildyushevskii AV, Karaulov AV. Limfoma kozhi. (Cutaneous lymphoma.) Moscow: BINOM Publ.; 2012. 183 p. (In Russ)]
  23. Братцева Е.В., Ротанов С.В. Современные подходы к диагностике грибовидного микоза. Вестник дерматологии и венерологии. 2010;6:16–22.
  24. [Brattseva EV, Rotanov SV. Current approaches to the diagnosis of mycosis fungoides. Vestnik dermatologii i venerologii. 2010;6:16–22. (In Russ)]
  25. Guitart J, Kennedy J, Ronan S, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001;28(4):174–83. doi: 10.1034/j.1600-0560.2001.028004174.x.
  26. Goteri G, Filosa A, Mannello B, et al. Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. J Clin Pathol. 2003;56(6):453–8. doi: 10.1136/jcp.56.6.453.
  27. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019:133(16):1703–14. doi: 10.1182/blood.2019002852.
  28. Белоусова И.Э., Казаков Д.В., Криволапов Ю.А. Современные подходы к диагностике и лечению первичных лимфом кожи на основе новой ВОЗ-EORTC классификации. Т-клеточные лимфомы кожи. Архив патологии. 2007;69(5):11–7.
  29. [Belousova IE, Kazakov DV, Krivolapov YuA. Current approaches to the diagnosis and treatment of primary cutaneous lymphomas based on the new WHO-EORTC classification. Cutaneous T-cell lymphomas. Arkhiv patologii. 2007;69(5):11–7. (In Russ)]
  30. Поддубная И.В., Птушкин В.В., Белоусова И.Э. и др. Новые возможности системной терапии CD30+ первичных кожных Т-клеточных лимфом: резолюция. Современная онкология. 2020;22(2):79–81.
  31. [Poddubnaya IV, Ptushkin VV, Belousova IE, et al. New prospects for systemic treatment of primary cutaneous CD30+ T-cell lymphomas: resolution. Sovremennaya onkologiya. 2020;22(2):79–81. (In Russ)]
  32. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006;176(7):4431–9. doi: 10.4049/jimmunol.176.7.4431.
  33. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol. 2010;130(2):362–70. doi: 10.1038/jid.2009.247.
  34. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269rv1. doi: 10.1126/scitranslmed.3010641.
  35. Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7(279):279ra39. doi: 10.1126/scitranslmed.3010302.
  36. Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers. 2016;8(3):36. doi: 10.3390/cancers8030036.
  37. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63. doi: 10.1146/annurev.immunol.22.012703.104702.
  38. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272(5258):60–7. doi: 10.1126/science.272.5260.
  39. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225–34. doi: 10.1038/ni889.
  40. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med. 2012;209(7):1241–53. doi: 10.1084/jem.20120994.
  41. Deenick EK, Cindy SM, Brink R, et al. Regulation of T follicular helper cell formation and function by antigen presenting cells. Curr Opin Immunol. 2011;23(1):111–8. doi: 10.1016/j.coi.2010.10.007.
  42. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2009;28:445–89. doi: 10.1146/annurev-immunol-030409-101212.
  43. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 2002;295(5553):336–8. doi: 10.1126/science.1065544.
  44. Bettelli E, Sullivan B, Szabo SJ, et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med. 2004;200(1):79–87. doi: 10.1084/jem.20031819.
  45. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol. 1994;103(5):669–73. doi: 10.1111/1523-1747.ep12398454.
  46. Miyagaki T, Sugaya M. Immunological milieu in mycosis fungoides and Sezary syndrome. J Dermatol. 2014;41(1):11–8. doi: 10.1111/1346-8138.12305.
  47. Hsi AC, Lee SJ, Rosman IS, et al. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications. J Am Acad Dermatol. 2015;72(1):159–67. doi: 10.1016/j.jaad.2014.09.022.
  48. Sugaya M, Tokura Y, Hamada T, et al. Phase II study of iv interferon‐gamma in Japanese patients with mycosis fungoides. J Dermatol. 2014;41(1):50–6. doi: 10.1111/1346-8138.12341.
  49. Gu X, Wang Y, Zhang G, Li W, Tu P. Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon‐induced apoptosis. J Dermatol. 2013;40(8):596–605. doi: 10.1111/1346-8138.12160.
  50. Kataoka Y. Thymus and activation‐regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol. 2014;41(3):221–9. doi: 10.1111/1346-8138.12440.
  51. Sugaya M, Morimura S, Suga H, Kawaguchi M. CCR 4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol. 2015;42(6):613–5. doi: 10.1111/1346-8138.12852.
  52. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000;192(11):1545–52. doi: 10.1084/jem.192.11.1545.
  53. Hardtke S, Ohl L, Forster R. Balanced expression of CXCR5 and CCR7 on follicular T helper cells determines their transient positioning to lymph node follicles and is essential for efficient B-cell help. Blood. 2005;106(6):1924–31. doi: 10.1182/blood-2004-11-4494.
  54. Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia. 2012;26(3):424–32. doi: 10.1038/leu.2011.237.
  55. Vonderheid EC, Pavlov I, Delgado JC, et al. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma. 2014;55(1):44–50. doi: 10.3109/10428194.2013.790541.
  56. Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056–60. doi: 10.1038/ng.3370.
  57. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
  58. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61. doi: 10.1016/j.ccell.2015.03.001.
  59. Cetinozman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in Sezary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379–85. doi: 10.1001/archdermatol.2012.2089.
  60. Kantekure K, Yang Y, Raghunath P, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF). Am J Dermatopathol. 2012;34(1):126. doi: 10.1097/dad.0b013e31821c35cb.
  61. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356–71. doi: 10.1038/s41571-019-0175-7.
  62. Clark RA. Regulation gone wrong: a subset of Sezary patients have malignant regulatory T cells. J Invest Dermatol. 2009;129(12):2747–50. doi: 10.1038/jid.2009.290.
  63. Gholami MD, Kardar GA, Saeedi Y, et al. Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms. Cell Immunol. 2017;322:1–14. doi: 10.1016/j.cellimm.2017.10.002.
  64. Murray D, McMurray JL, Eldershaw S, et al. Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR. Blood Adv. 2019:3(4):519–30. doi: 10.1182/bloodadvances.2018025114.
  65. Vermeer MH, van Doorn R, Dukers D, et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol. 2001;19(23):4322–9. doi: 10.1200/jco.2001.19.23.4322.
  66. Goteri G, Filosa A, Mannello B, et al. Density of neoplastic lymphoid infiltrate, CD8+ T cells, and CD1a+ dendritic cells in mycosis fungoides. J Clin Pathol. 2003;56(6):453–8. doi: 10.1136/jcp.56.6.453.
  67. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol. 1995;32(3):448–53. doi: 10.1016/0190-9622(95)90067-5.
  68. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21(12):2512–8. doi: 10.1038/sj.leu.2404913.
  69. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood. 2002;99(8):2929–39. doi: 10.1182/blood.v99.8.2929.
  70. Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides–cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(1):212–9. doi: 10.1038/sj.jid.5700029.
  71. Querfeld C, Curran SA, Leung S, et al. T cells in CTCL have an exhausted phenotype while cutaneous dendritic cells display a normally activated mature phenotype. Blood. 2014;124(21):1695. doi: 10.1182/blood.v124.21.1695.1695.
  72. Sugaya M, Miyagaki T, Ohmatsu H, et al. Association of the numbers of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci. 2012;68(1):45–51. doi: 10.1016/j.jdermsci.2012.07.007.
  73. Wu X, Schulte BC, Zhou Y, et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014;134(11):2814–22. doi: 10.1038/jid.2014.206.
  74. Jullie ML, Carlotti M, Vivot A Jr, et al. CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact Am J Surg Pathol. 2013;37(12):1845–54. doi: 10.1097/pas.0000000000000091.
  75. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977–82. doi: 10.4049/jimmunol.1001323.
  76. Theurich S, Schlaak M, Steguweit H, et al. Targeting tumor-infiltrating B cells in cutaneous T-cell lymphoma. J Clin Oncol. 2016;34(12):e110–e116. doi: 10.1200/jco.2013.50.9471.
  77. Choi J, Goh G, Walradt T, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–9. doi: 10.1038/ng.3356.
  78. Park J, Yang J, Wenzel AT, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p. Q575E). Blood. 2017;130(12):1430–40. doi: 10.1182/blood-2017-02-768234.
  79. Gonzalez BR, Zain J, Rosen ST, Querfeld C. Tumor microenvironment in mycosis fungoides and Sezary syndrome. Curr Opin Oncol. 2016;28(1):88–96. doi: 10.1097/CCO.0000000000000243
  80. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. 1992;267(10):1354–8. doi: 10.1001/jama.267.10.1354.
  81. Netchiporouk E, Litvinov IV, Moreau L, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331–5. doi: 10.4161/15384101.2014.965061.
  82. Kirsch IR, Watanabe R, O’Malley JT, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Science Transl Med. 2015;7(308):308ra158. doi: 10.1126/scitranslmed.aaa9122.
  83. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди, 2016. С. 85–91.
  84. [Poddubnaya IV, Savchenko VG, eds. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (Russian clinical guidelines on diagnosis and treatment of lymphoproliferative disorders.) Moscow: Buki Vedi Publ.; 2016. 85–91. (In Russ)]
  85. Сидорова Ю.В. Т-клеточная клональность в диагностике лимфопролиферативных заболеваний: Дис.… канд. мед. наук. М., 2004.
  86. [Sidorova YuV. T-kletochnaya klonalnost v diagnostike limfoproliferativnykh zabolevanii. (T-cell clonality in the diagnosis of lymphoproliferative) [dissertation] Moscow; 2004. (In Russ)]
  87. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–22. doi: 10.1182/blood-2008-02-142653.
  88. Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766. doi: 10.1200/JCO.2015.61.7142.
  89. de Masson A, O’Malley JT, Elco CP, et al. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med. 2018;10(440):eaar5894. doi: 10.1126/scitranslmed.aar5894.
  90. Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome–Update 2017. Eur J Cancer. 2017;77:57–74. doi: 10.1016/j.ejca.2017.02.027.
  91. Олисова О.Ю., Сыдиков А.А., Чупров И.Н. и др. Эритродермическая форма грибовидного микоза: алгоритм диагностики и лечения. Клиническая онкогематология. 2018;11(4):295–302. doi: 10.21320/2500-2139-2018-11-4-295-302.
  92. [Olisova OYu, Sydikov AA, Chuprov IN, et al. Erythrodermic Mycosis Fungoides: The Algorithm of Diagnosis and Treatment. Clinical oncohematology. 2018;11(4):295–302. doi: 10.21320/2500-2139-2018-11-4-295-302. (In Russ)]
  93. Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860–3. doi: 10.1093/annonc/mdp508.
  94. Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sezary syndrome. Am J Hematol. 2016;91(12):E491–E495. doi: 10.1002/ajh.24564.
  95. Damsky WE, Choi J. Genetics of cutaneous T cell lymphoma: from bench to bedside. Curr Treat Options Oncol. 2016;17(7):1–14. doi: 10.1007/s11864-016-0410-8.
  96. Weng WK, Armstrong R, Arai S, et al. Non-myeloablative allogeneic transplantation resulting in clinical and molecular remission with low Non-Relapse Mortality (NRM) in patients with advanced stage Mycosis Fungoides (MF) and Sezary Syndrome (SS). Blood. 2014;124(21):2544. doi: 10.1182/blood.v124.21.2544.2544.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.